F
Federica Pergolesi
Publications - 6
Citations - 364
Federica Pergolesi is an academic researcher. The author has contributed to research in topics: Medicine & Cohort. The author has an hindex of 4, co-authored 5 publications receiving 180 citations.
Papers
More filters
Journal ArticleDOI
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini,Melissa Bersanelli,Sebastiano Buti,Katia Cannita,Daniele Santini,Fabiana Perrone,Raffaele Giusti,Marcello Tiseo,Maria Michiara,Pietro Di Marino,Nicola Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Riccardo Marconcini,Francesco Malorgio,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Gian Carlo Antonini Cappellini,Federica De Galitiis,Maria Giuseppa Vitale,Francesca Rastelli,Federica Pergolesi,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Rita Chiari,Biagio Ricciuti,Andrea De Giglio,Daniela Iacono,Alain Gelibter,Mario Occhipinti,Alessandro Parisi,Giampiero Porzio,Maria Concetta Fargnoli,Paolo A. Ascierto,Corrado Ficorella,Clara Natoli +44 more
TL;DR: Overweight could be considered a tumorigenic immune-dysfunction that could be effectively reversed by ICIs and BMI could be a useful predictive tool in clinical practice and a stratification factor in prospective clinical trials with ICIs.
Journal ArticleDOI
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index
Sebastiano Buti,Melissa Bersanelli,Fabiana Perrone,Marcello Tiseo,Marco Tucci,Vincenzo Adamo,Luigia Stefania Stucci,Alessandro Russo,Enrica Teresa Tanda,Francesco Spagnolo,Francesca Rastelli,Federica Pergolesi,Daniele Santini,Marco Russano,Cecilia Anesi,Raffaele Giusti,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Alain Gelibter,Mario Occhipinti,Marco Ferrari,Maria Giuseppa Vitale,Linda Nicolardi,Rita Chiari,Erika Rijavec,Olga Nigro,Alessandro Tuzi,Michele De Tursi,Pietro Di Marino,Fabio Conforti,Paola Queirolo,Sergio Bracarda,Serena Macrini,Stefania Gori,Federica Zoratto,Enzo Veltri,Barbara Di Cocco,Domenico Mallardo,Maria Grazia Vitale,Matteo Santoni,Leonardo Patruno,Giampiero Porzio,Corrado Ficorella,David J. Pinato,Paolo A. Ascierto,Alessio Cortellini +46 more
TL;DR: Cumulative exposure to corticosteroids, antibiotics and PPIs (three likely microbiota-modulating drugs) leads to progressively worse outcomes after ICI therapy, and a simple prognostic score is proposed that can help stratifying patients in routine practice and clinical trials of ICIs.
Journal ArticleDOI
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
Alessio Cortellini,Maria Grazia Vitale,Federica De Galitiis,Francesca Di Pietro,Rossana Berardi,Mariangela Torniai,Michele De Tursi,Antonino Grassadonia,Pietro Di Marino,Daniele Santini,Tea Zeppola,Cecilia Anesi,Alain Gelibter,Mario Occhipinti,Andrea Botticelli,Paolo Marchetti,Francesca Rastelli,Federica Pergolesi,Marianna Tudini,Rosa Rita Silva,Domenico Mallardo,Vito Vanella,Corrado Ficorella,Giampiero Porzio,Paolo A. Ascierto +24 more
TL;DR: Early ir-fatigue seems to be negative prognostic parameter, but to proper weight its role the authors must to consider the predominant role of performance status, which was related to early ir-Fatigue in the study population.
Journal ArticleDOI
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Marco Russano,Alessio Cortellini,Raffaele Giusti,Alessandro Russo,Federica Zoratto,Francesca Rastelli,Alain Gelibter,Rita Chiari,Olga Nigro,Michele De Tursi,Sergio Bracarda,Stefania Gori,Francesco Grossi,Melissa Bersanelli,Lorenzo Calvetti,Vincenzo Di Noia,Mario Scartozzi,Massimo Di Maio,Paolo Bossi,Alfredo Falcone,Fabrizio Citarella,Francesco Pantano,Corrado Ficorella,Marco Filetti,Vincenzo Adamo,Enzo Veltri,Federica Pergolesi,Mario Occhipinti,Linda Nicolardi,Alessandro Tuzi,Pietro Di Marino,Serena Macrini,Alessandro Inno,Michele Ghidini,Sebastiano Buti,Giuseppe Aprile,Eleonora Lai,Marco Audisio,Salvatore Intagliata,Riccardo Marconcini,Davide Brocco,Giampiero Porzio,Marta Piras,Erika Rijavec,Francesca Simionato,Clara Natoli,Marcello Tiseo,Bruno Vincenzi,Giuseppe Tonini,Daniele Santini +49 more
TL;DR: In this paper, the prognostic relevance of early immune-related adverse events (irAEs) in patients affected by non-small cell lung cancer (NSCLC) upon immunotherapy is not fully understood.
Journal ArticleDOI
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.
Alessio Cortellini,Sebastiano Buti,Melissa Bersanelli,Raffaele Giusti,Fabiana Perrone,Pietro Di Marino,Nicola Tinari,Michele De Tursi,Antonino Grassadonia,Katia Cannita,Alessandra Tessitore,Federica Zoratto,Enzo Veltri,Francesco Malorgio,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Gian Carlo Antonini Cappellini,Federica De Galitiis,Maria Giuseppa Vitale,Francesca Rastelli,Federica Pergolesi,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Daniela Iacono,Maria Rita Migliorino,Alain Gelibter,Mario Occhipinti,Francesco Martella,Alessandro Inno,Stefania Gori,Sergio Bracarda,Cristina Zannori,Claudia Mosillo,Alessandro Parisi,Giampiero Porzio,Domenico Mallardo,Maria Concetta Fargnoli,Marcello Tiseo,Daniele Santini,Paolo A. Ascierto,Corrado Ficorella +48 more
TL;DR: FHC-high patients seem to benefit more than FHC-negative patients from anti-PD-1/PD-L1 checkpoint inhibitors, and the role of family history of cancer (FHC) and diagnosis of metachronous and/or synchronous multiple neoplasms (MN) is investigated.